Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19.

Tianchuan ZhuYuchen XiaoXiaojun MengLantian TangBin LiZhaoyan ZhaoQingqin TanHong ShanLei LiuXi Huang

Published in: Journal of nanobiotechnology (2021)

In summary, we demonstrate that nanovesicles derived from CAR-T cells targeting the spike protein of SARS-COV-2 have the ability to neutralize Spike-pseudotyped virus and target antiviral drugs. This novel therapeutic approach may help to solve the dilemma faced by neutralizing antibodies and small-molecule drugs in the treatment of COVID-19.

Keyphrases

sars cov
small molecule
protein protein
respiratory syndrome coronavirus
cancer therapy
coronavirus disease
amino acid
binding protein
dengue virus
combination therapy
zika virus
drug induced
replacement therapy
smoking cessation